Summary
RC-160 (octastatin/vapreotide) is a potent octapeptide analogue of somatostatin with growth inhibitory activity in experimental tumours in vitro and in vivo, including breast cancer. We evaluated the efficacy and tolerability of high-dose RC-160, 3 mg day–1 on week 1 increased to 4.5 mg day–1 for weeks 2–4 and subsequently 6 mg day–1 until the end of treatment, administered by continuous subcutaneous infusion in the management of 14 women with previously treated metastatic breast cancer. The age range was 37–80 years (median 58.5 years) and performance status 0–2. The treatment was well tolerated with no dose reductions being required. No grade 3 or 4 toxicities were seen. Abscess formation developed at the infusion site in eight patients and erythema and discomfort was seen in a further three patients. A significant reduction in IGF-I levels occurred by day 7 and was maintained throughout the treatment. The lowest dose of RC-160 produced the maximal IGF-I response. Although there was no reduction in prolactin levels in patients whose baseline levels were normal, elevated prolactin levels found in three patients fell to within the normal range 7 days after commencing RC-160 treatment. A small but significant rise in fasting blood glucose levels was also recorded, the highest level on treatment being 7.6 mmol l–1. No objective tumour responses were observed, all patients showing disease progression within 3 months of commencing treatment. These findings demonstrate that high-dose RC-160, administered as a continuous subcutaneous infusion, can reduce serum levels of the breast growth factors IGF-I and prolactin but is ineffective in the management of metastatic breast cancer. Encouraging preclinical anti-tumour activity and the favourable toxicity profile in patients suggest the merit of future studies combining RC-160 with anti-oestrogen, cytotoxic and anti-angiogenic agents.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bates, P., Fisher, R., Ward, A., Richardson, L., Hill, D. J. & Graham, C. F. (1995). Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF II). Br J Cancer 72: 1189–1193.
Battersill, P. E. & Clissold, S. P. (1989). Octreotide: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs 38: 658–702.
Bontenbal, M., Foekens, J. A., Lamberts, S. W. J., de Jong, F. H., van Putten, W. L. J., Braun, H. J., Burghouts, JThM, van der Linden, G. H. M. & Klign, J. G. M. (1998). Feasibility, endocrine and anti-tumour effects of a triple endocrine therapy with tamoxifen, a somatostatin analogue and an antiprolactin in post-menopausal metastatic breast cancer: a randomised study with long-term follow-up. Br J Cancer 77: 115–122.
Brower, S. T., Schally, A. V., Redding, T. W. & Hollander, V. P. (1992). Differential effects of LHRH and somatostatin analogs on human breast cancer. J Surg Res 52: 6–14.
Bruns, C., Weckbecker, G., Raulf, F., Kaupmann, K., Schoesster, P., Hoyer, D. & Lubbert, H. (1994). Molecular pharmacology of somatostatin receptor subtypes. Ann NY Acad Sci 733: 138–146.
Buscail, L., Delesque, N., Esteve, J-P, Saint-Laurent, N., Prats, H., Clerc, P., Robberecht, P., Bell, G. I., Liebow, C., Schally, A. V., Vaysse, N. & Susini, C. (1994). Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTRI and SSTR2. Proc Natl Acad Sci USA 91: 2315–2319.
Buscail, L., Esteve, J-P, Saint-Laurent, N., Bertrand, V., Reisine, T., O’Carroll, A-M, Bell, G. I., Schally, A. V., Vaysse, N. & Susini, C. (1995). Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92: 1580–1584.
Cai, R-Z, Szoye, B., Lu, R., Fu, D., Redding, T. W. & Schally, A. V. (1986). Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc Natl Acad Sci USA 83: 1896–1900.
Candi, E., Melino, G., De Laurenzi, V., Piacentini, M., Guerrieri, P., Spinedi, A. & Knight, R. A. (1995). Tamoxifen and somatostatin affect tumours by inducing apoptosis. Cancer Lett 96: 141–143.
Canobbio, L., Cannata, D., Miglietta, L. & Boccardo, F. (1995). Somatuline (BIM 23014) and tamoxifen treatment of postmenopausal breast cancer patients: clinical activity and effect on insulin-like growth factor-I (IGF-I) levels. Anticancer Res 15: 2687–2690.
Caron, P., Morange-Ramos, I., Cogne, M. & Jaquet, P. (1997). Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 82: 18–22.
Chan, J. M., Stampfer, M. J., Giovannucci, E., Gann, P. H., Ma, J., Wilkinson, P., Hennekens, C. H. & Pollak, M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 279: 563–566.
Clevenger, C. V., Chang, W. P., Ngo, W., Pasha, T. L., Montone, K. T. & Tomaszewski, J. E. (1995). Expression of prolactin and prolactin receptor in human breast carcinoma. Evidence for an autocrine/paracrine loop. Am J Path 146: 695–705.
Cordelier, P., Esteve, J-P, Bousquet, C., Delesque, N., O’Carroll, A-M, Schally, A. V., Vaysse, N., Susini, C. & Buscail, L. (1997). Characterization of the anti-proliferative signal mediated by the somatostatin receptor subtypes sst5. Proc Natl Acad Sci USA 94: 9343–9348.
Das, R. & Vonderhaar, B. K. (1996). Activation of raf-1, MEK, and MAP kinase in prolactin responsive mammary cells. Breast Cancer Res Treat 40: 141–149.
Di Leo, A., Ferrari, L., Bajetta, E., Bartoli, C., Vicario, G., Moglia, D., Miceli, R., Callegari, M. & Bono, A. (1995). Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. group. Italian trials in medical oncology. Breast Cancer Res Treat 34: 237–244.
Erwin, R. A., Kirken, R. A. & Malabarba, M. G. (1995). Prolactin activates ras via signalling proteins SHC, growth factor receptor bound 2, and son of sevenless. Endocrinology 136: 3512–3518.
Evans, A. A., Crook, T., Laws, S. A. M., Gough, A. C., Royle, G. T. & Primrose, J. N. (1997). Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer 75: 798–803.
Folkman, J. (1995). Clinical applications of research on angiogenesis. N Engl J Med 333: 1757–1763.
Goldhirsch, A. & Gelber, R. D. (1996). Endocrine therapies of breast cancer. Semin Oncol 23: 494–505.
Gonzalez-Barcena, D., Molina-Ayala, M. A., Cortez-Morales, A., Vadillo-Buenfil, M., Cardenas-Cornejo, I., Comaru-Schally, A. M. & Schally, A. V. (1998). Response to administration of somatostatin analog RC-160 (vapreotide) in patients with advanced prostatic cancer at the relapse time. Proc 80th Annual Meeting Endocrine Soc, pp 421, abstract 164
Hankinson, S. E., Willett, W. C., Colditz, G. A., Hunter, D. J., Michaud, D. S., Deroo, B., Rosner, B., Speizer, F. E. & Pollak, M. (1998). Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393–1396.
Hayes, D. F., Henderson, I. C. & Shapiro, C. L. (1995). Treatment of metastatic breast cancer: present and future prospects. Semin Oncol 22 (suppl. 5): 5–21.
Helle, S. I., Geisler, J., Poulsen, J. P., Hestdal, K., Meadows, K., Collins, W., Tveit, K. M., Viste, A., Holly, J. M. P. & Lonning, P. E. (1998). Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study. Br J Cancer 78: 14–20.
Helle, S. I. & Lonning, P. E. (1996). Insulin-like growth factors in breast cancer. Acta Oncol 35(suppl. 5): 19–22.
Hofland, L. J., van Koetsfeld, P. M., Waajers, M., Zuyderwijk, J. & Lamberts, S. W. J. (1994). Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology 134: 301–306.
Holly, J. (1998). Insulin-like growth factor-I and new opportunities for cancer prevention. Lancet 351: 1373–1375.
Ingle, J. N., Kardinal, C. G., Suman, V. J., Krook, J. E. & Hatfield, A. K. (1996). Octreotide as first-line treatment for women with metastatic breast cancer. Invest New Drugs 14: 235–237.
Klijn, J. G. M., Berns, PMJJ & Foekens, J. A. (1993). Prognostic factors and response to therapy in breast cancer. Cancer Surv 18: 165–198.
Lamberts, S. W. J., Krenning, E. P. & Reubi, J. (1991). The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrine Rev 12: 450–482.
Lee, J. M., Erlich, R. B., Bruckner, H. W., Szrajer, L. & Ohnuma, T. (1993). A somatostatin analogue (SMS 201-995) alters the toxicity of 5-fluorouracil in Swiss mice. Anticancer Res 13: 1453–1456.
Liebow, C., Reilly, C., Serrano, M. & Schally, A. V. (1988). Somatostatin analogs inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 85: 1–22.
Macaulay, V. M. (1992). Insulin-like growth factors and cancer. Br J Cancer 65: 311–320.
Manni, A., Boucher, A. E., Demers, L. M., Harvey, H. A., Lipton, A., Symmonds, M. A. & Bartholomew, M. (1989). Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14: 289–298.
Morere, J. F., Cour, V., Breau, J. L., Boaziz, C., Basin, C. & Israel, L. (1989). Stabilising effect of BIM23014, a long acting somatostatin analog in 30 cases of advanced breast cancer: a phase II study. Proc Am Soc Clin Oncol 8: 47 (abstract 179)
Nagy, A., Schally, A. V., Halmos, G., Armatis, P., Cai, R-Z, Csernus, V., Kovacs, M., Koppan, M., Szepeshazi, K. & Kahan, Z. (1998). Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 95: 1794–1799.
Patel, P. C., Barrie, R., Hill, N., Landeck, S., Kurozawa, D. & Woltering, E. A. (1994). Postreceptor signal transduction mechanisms involved in octreotide induced inhibition of angiogenesis. Surgery 116: 1148–1152.
Pinski, J., Schally, A. V., Halmos, G., Szepeshazi, K., Groot, K., O’Byrne, K. J. & Cai, R-Z (1994). Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer 70: 886–892.
Pinski, J., Schally, A. V., Halmos, G., Szepeshazi, K. & Groot, K. (1996). Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer 65: 870–874.
Pollak, M. (1996). Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 57 (suppl 1): 29–33.
Pollak, M. & Schally, A. V. (1998). Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 217: 143–152.
Poston, G. J. & Schally, A. V. (1993). Somatostatin analogs and pancreatic cancer. Int J Pancreatology 14: 64–66.
Prevost, G. & Israel, L. (1993). Somatostatin and somatostatin analogues in human breast carcinoma. Recent Results Cancer Res 129: 63–70.
Qin, Y., Eftl, T., Groot, K., Horvath, J., Cai, R-Z & Schally, A. V. (1995). Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular production of cyclic adenosine monophosphate. Int J Cancer 60: 694–700.
Reichlin, S. (1983a). Somatostatin (First of two parts). N Engl J Med 309: 1495–1501.
Reichlin, S. (1983b). Somatostatin (Second of two parts). N Engl J Med 309: 1556–1563.
Schally, A. V. (1988). Oncological applications of somatostatin analogues. Cancer Res 48: 6977–6985.
Setyano-Han, B., Henkelman, M. S., Foekens, J. A. & Klijn, J. G. M. (1987). Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 47: 1566–1570.
Srkalovic, G., Szende, B., Redding, T. W., Groot, K. & Schally, A. V. (1989). Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma (42987). Proc Soc Exp Biol Med 192: 209–218.
Stolfi, R., Parisi, A. M., Natoli, C. & Iacobelli, S. (1990). Advanced breast cancer: response to somatostatin. Anticancer Res 10: 203–204.
Szende, B., Lapis, K., Redding, T. W., Srkalovic, G. & Schally, A. V. (1989). Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin. Breast Cancer Treat Res 14: 307–314.
Szende, B., Schally, A. V. & Lapis, K. (1991). Immunocytochemical demonstration of tissue transglutaminase indicative of programmed cell death (apoptosis) in hormone sensitive mammary tumours. Acta Morphol Hung 39: 53–58.
Szepeshazi, K., Lapis, K. & Schally, A. V. (1991). Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer 49: 260–266.
Szepeshazi, K., Milovanovic, S., Lapis, K., Groot, K. & Schally, A. V. (1992). Growth inhibition of oestrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH, an analog of somatostatin, or a combination. Breast Cancer Res Treat 21: 181–192.
Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N. & Brem, H. (1994). Potentiation of cytotoxic cancer therapies by TNP470 alone and with other anti-angiogenic agents. Int J Cancer 57: 920–925.
Tornell, J., Carlsson, B., Pohjanen, P., Wennbo, H., Rymo, L. & Isaksson, O. G. P. (1992). High frequency of mammary adenocarcinomas in metallothionein promoter-human growth hormone transgenic mice created from two different strains of mice. J Steroid Biochem Mol Biol 43: 237–242.
Van Eijck, C. H. J., Krenning, E. P., Bootsma, A., Oei, H. Y., Van Pel, R., Lindesmans, J., Jeekel, J., Reubi, J-C & Lamberts, S. W. J. (1994). Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343: 640–643.
Vennin, P. H., Peyrat, J. P., Bonneterre, J., Louchez, M. M., Harris, A. G. & Demaille, A. (1989). Effect of the long-acting somatostatin analogue SMS 201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9: 153–156.
Weckbecker, G., Tolcsvai, L., Stolz, B., Pollak, M. & Bruns, C. (1994). Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinoma. Cancer Res 54: 6334–6337.
Weckbecker, G., Raulf, F., Tolcsvai, L. & Bruns, C. (1996). Potentiation of the anti-proliferative effects of anti-cancer drugs by octreotide in vitro and in vivo. Digestion 57 (suppl. 1): 22–28.
Xu, Y., Song, J., Berelowitz, M. & Bruno, J. F. (1996). Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 137: 5634–5640.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
O’Byrne, K., Dobbs, N., Propper, D. et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 79, 1413–1418 (1999). https://doi.org/10.1038/sj.bjc.6690226
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690226
Keywords
This article is cited by
-
Evaluation of IGF-I levels during long-term somatostatin analogs treatment in patients with gastroenteropancreatic endocrine tumors
Journal of Endocrinological Investigation (2007)
-
Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours
British Journal of Cancer (2002)